

Special Issue

Arrhythmic Risk Stratification

Message from the Guest Editors

Sudden cardiac death is a relevant problem, accounting for 50% of all cardiovascular deaths. In 50% of cases, it is the first manifestation of the disease, with an increasing incidence with age. The latest ESC 2022 guidelines emphasize the importance of a correct diagnostic evaluation and arrhythmia risk stratification in different clinical scenarios, with interesting updates regarding the role of cardiac magnetic resonance imaging and genetics. They also emphasize the importance of a multidisciplinary approach to the management of high-risk patients, involving clinical cardiologists, electrophysiologists, and cardiac imaging experts. However, many patients still fall into a gray area for whom it can be difficult to make a right decision. The aim of this Special Issue is to collect your experiences and ideas on "arrhythmic risk stratification" of patients with different forms of cardiomyopathy and channelopathy in review articles and clinical research articles, so that we can discuss this topic, which still raises many open questions, with the aim of improving the management of our patients.

Guest Editors

Dr. Marisa Varrenti

De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, 20126 Milan, Italy

Dr. Patrizio Mazzone

De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, 20126 Milan, Italy

Deadline for manuscript submissions

closed (15 January 2024)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.6
Indexed in PubMed



mdpi.com/si/166194

*Journal of Cardiovascular
Development and Disease*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

mdpi.com/journal/

[jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.6
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed,
PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 22.9 days after
submission; acceptance to publication is undertaken in 2.6
days (median values for papers published in this journal in
the first half of 2024).